GlassScriptPhysician profile
John J Huang
NPI 1801822754
$266,788.48
in general payments reported to CMS, 2019-2025
29 companies · $46K in 2025
The $46K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $59K · 2021: $22K · 2022: $28K · 2023: $31K · 2024: $47K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Consulting Fee: $9,200 · Food and Beverage: $5,510 · Travel and Lodging: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,493.00 |
| Consulting Fee | $9,200.00 |
| Food and Beverage | $5,509.57 |
| Travel and Lodging | $1,726.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $84,779.45 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $52,506.51 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $40,748.19 | 2023-2025 | Izervay |
| Allergan, INC. | $27,347.56 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $17,630.95 | 2019 | |
| Coherus Oncology, INC. | $14,185.10 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,345.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $8,051.32 | 2019-2023 | |
| Abbvie INC. | $4,336.58 | 2019-2025 | |
| Eyepoint US, INC. | $3,540.10 | 2019-2023 | |
| Biogen, INC. | $1,176.93 | 2022 | |
| Genentech USA, INC. | $612.11 | 2019-2025 | Vabysmo, Xolair |
| Sandoz INC. | $550.14 | 2024-2025 | Cimerli |
| Alimera Sciences, INC. | $385.87 | 2021-2024 | Iluvien, Yutiq |
| Novo Nordisk INC | $277.66 | 2019-2023 | Wegovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $241.13 | 2023-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Ocular Therapeutix, INC. | $168.32 | 2019-2021 | |
| Alcon Vision LLC | $167.04 | 2019-2022 | |
| Genentech, INC. | $143.27 | 2024 | Vabysmo |
| Spark Therapeutics, INC. | $125.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.62 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $89.67 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $81.11 | 2022 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Oyster Point Pharma, INC. | $53.76 | 2022-2023 | Tyrvaya |
| Amgen INC. | $51.38 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $17.66 | 2025 | Iheezo |
| Omeros Corporation | $16.41 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.